We Like Zimmer's Pick for CEO
We think he’ll bring a much-needed new perspective to the company.
We think he’ll bring a much-needed new perspective to the company.
Editor's note: At the time of publication (Dec. 20, 2017), a family member of the analyst owned shares in Stryker (SYK) in an account managed by a third party. Morningstar has confirmed that her ownership of Stryker did not influence any ratings or analysis.
We’re pleased with Zimmer Biomet’s (ZBH) choice of president and CEO, and we’re leaving our fair value estimate and wide economic moat rating unchanged.
Debbie Wang does not own shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.